Bionic Biologics for better medicines
Grove Biopharma is pioneering Bionic Biologics™, a breakthrough synthetic modality for developing novel therapeutics that target intracellular protein-protein interactions.
Bionic Biologics
Bionic
Hybrid biomolecules that integrate biologic function with synthetic precision to create a new class of medicines.
Cell permeable
Designed to reach intracellular targets that have historically been beyond the reach of biologics.
AI enabled
Combining AI-guided molecular design with modular chemistry, Grove rapidly designs and develops mono- or multifunctional molecules against virtually any target.
Unlocking the next frontier in drug discovery
At Grove Biopharma, we’re striving for better medicines for patients living with cancer, neurodegenerative diseases, and rare disorders.
Proteins are the molecular machines that drive all essential cellular functions. Dysregulated intracellular protein-protein interactions (PPIs) are at the core of most devastating human diseases. Yet most intracellular PPIs have remained beyond the reach of existing drug modalities because they cannot effectively enter cells or engage the large, complex surfaces that govern these interactions.
By combining AI-based de novo peptide design with precision polymer chemistry, our Bionic Biologics platform transform peptides – natural mediators of protein interactions – into synthetic biologics uniquely suited to target intracellular PPIs. The result is the design of cell-permeable molecules capable of disrupting or degrading disease-causing target proteins, bringing previously inaccessible intracellular targets within reach.
Bionic Biologics have demonstrated proof-of-concept across several validated yet formidable intracellular targets
Breakthrough synthetic chemistry, made in Chicago
Grove Biopharma is a multidisciplinary team of chemists, biologists, AI experts, materials scientists, and entrepreneurs working together to advance a new synthetic drug modality with transformative potential for patients.
We are headquartered in the heart of Chicago with a powerful compute infrastructure in Toronto and proud to contribute to the regions’ emerging life sciences ecosystems.
Grove Biopharma Reports Preclinical Study in Nature Communications Demonstrating a Novel Approach to MYC and KRAS Degradation
February 24, 2026
Heterobifunctional proteomimetic polymers for targeted degradation of MYC and KRAS
February 24, 2026
Geoffrey Duyk, Grove Biopharma CEO, on Polymer Breakthroughs, Intractable Targets & Biotech's Future
October 23, 2025
Grove Biopharma to Participate in Materials Biology Symposium at ACS Fall 2025 Scientific Meeting
August 15, 2025
Injectable Protein-Like Polymers Protect Rodent Heart After Myocardial Infarction
April 29, 2025
Protein-Like Polymers Targeting Keap1/Nrf2 as Therapeutics for Myocardial Infarction
April 25, 2025
Building Biotech at the Interface: Geoff Duyk on Genomics, Platforms, and Grove Biopharma
April 24, 2025
